The Chhattisgarh health department is taking decisive action against pharmaceutical companies failing to meet quality standards. M/s. Effi Parenterals has been issued a show-cause notice and faces potential blacklisting after substandard quality was found in their drug supply. The department’s policy is to ensure all medicines provided to health institutions pass rigorous quality tests performed by NABL-accredited laboratories. The drug testing procedures discovered deficiencies in the Albendazole tablets IP 400 mg (Drug Code – D12), batches PGT25451, PGT25450, PGT25480, and PGT25229, supplied to the government. The State Drug Testing and Research Laboratory, Raipur, conducted the tests, which resulted in the batches being deemed unfit for use. The company has been instructed to recall the defective batches from all relevant warehouses.
